Genetic engineering concept. Medical science. Scientific Laboratory.

Blog

image-

APDN Secures Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates

Posted on

STONY BROOK, N.Y. – June 9, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company,” “our”) announced today it secured a $40,000 economic development grant from National Grid to support the Company’s efforts associated with the manufacture of COVID-19-related therapeutics and diagnostics programs. National Grid is one of the largest investor-owned […]

Read More email

image-

APDN Provides Update on Linear-DNA COVID-19 Vaccine Candidates Development Program

Posted on

STONY BROOK, N.Y. – June 8, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the  “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today provided an update related to the development of […]

Read More email

image-

APDN to Participate in Maxim Group’s COVID-19 Virtual Conference Series on May 27

Posted on

STONY BROOK, N.Y., May 21, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, announced that Dr. James Hayward, president & CEO, will participate on a […]

Read More email

image-

APDN and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals

Posted on

Beyond expectations, a single injection of DNA in mice induced antibodies that block the infection of cultured human cells by SARS-CoV-2 STONY BROOK, N.Y. and Rome, Italy – May 4, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company” or “we/our”) today announced with its COVID-19 vaccine development partner Takis Biotech […]

Read More email

image-

Italian Biotech Startup Racing To Develop A Coronavirus Vaccine

Posted on

Four days before the first cases of COVID-19 were confirmed in Italy on January 31, a small biotech firm in the outskirts of Rome announced it was pivoting its business. Researchers at Takis Biotech, which had been focused on cancer treatments, would instead set about developing a vaccine for the rapidly spreading coronavirus. With the virus […]

Read More email

image-

APDN High-Sensitivity and High-Throughput COVID-19 Diagnostic Kit Enters Validation Process in Partnership with Stony Brook University Hospital

Posted on

Paves Path for Application to FDA for Emergency Use Authorization before end of April 2020; Company providing high-throughput RNA-extraction robotics and enhanced-sensitivity RT-qPCR assay with goals to diminish false negatives, quantify viral loads and enhance testing volumes for the region STONY BROOK, N.Y. April 21, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” […]

Read More email

image-

LI Biotech Speeds COVID-19 Vaccine Candidates To Italy

Posted on

Cure bet: If vaccine candidates prepared by Applied DNA’s LinearDNA manufacturing system perform as well as plasmid-based candidates prepared by Italian biopharma Takis Biopharma, the cross-Atlantic collaboration may be on to something. APRIL 15, 2020 By GREGORY ZELLER // With preliminary lab tests looking good, an innovative Long Island biotech is rushing a quintet of […]

Read More email

image-

APDN Ships COVID-19 LinearDNA™ Vaccine Candidates to Italian Development Partner to Begin Preclinical Animal Testing

Posted on

STONY BROOK, N.Y., and ROME, ITALY. April 15, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced that it has completed design qualification, production […]

Read More email

image-

APDN to Speak on COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5

Posted on

STONY BROOK, N.Y., April 14, 2020 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced its participation at Maxim Group’s Infectious Disease Virtual Conference on […]

Read More email

image-

APDN Ships LinearDNA™ to Another Development Customer

Posted on

STONY BROOK, N.Y., March 26, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, announced today that it has shipped two CAR T amplicons proprietary to […]

Read More email